-
Mashup Score: 4Oral Nirmatrelvir and Ritonavir for Covid-19 in Vaccinated, Non-Hospitalized Adults, Ages 18-50 Years - 10 month(s) ago
NMV-r use for Covid-19 in vaccinated adults aged 18-50, with serious comorbidities, was associated with improved clinical outcomes. However, patients without si
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Former Pfizer statistician is charged with insider trading over Paxlovid clinical trial results - 10 month(s) ago
A former Pfizer statistician was charged by U.S. authorities with insider trading for acting on advance information about trial results for the Paxlovid Covid-19 treatment.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
Former Pfizer statistician is charged with insider trading over Paxlovid clinical trial results.. https://t.co/GLkKXMvDRd #pharma #insidertrading #Paxlovid #clinicaltrials $PFE
-
-
Mashup Score: 0New antiviral, Paxlovid, added to PANORAMIC study - 11 month(s) ago
From today, the antiviral treatment Paxlovid has been included in the national PANORAMIC study, the UK’s fastest ever recruiting clinical trial of its kind, run by the Nuffield Department of Primary Care Health Sciences and supported by the National Institute for Health and Care research (NIHR).
Source: www.panoramictrial.orgCategories: Expert Picks, Latest HeadlinesTweet-
For a non-eradicable pathogen, vaccines and antivirals (#therapeutics) both important so vulnerable can be protected. Here is another (observational) study showing benefit of #Paxlovid in high-risk (Panoramic UK study underway https://t.co/TcNjLysoda) https://t.co/hyv0bQS44I
-
-
Mashup Score: 0Staying Current With Drug Interactions - 12 month(s) ago
A clinician provides insights on this significant topic as well as resources in finding information on them.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
Dr. Douglas Paauw @UWMedicine provides some resources and insights on drug interactions at the recent @ACPIMPhysicians meeting. #MedTwitter #IDtwitter #Paxlovid Check out the interview here: https://t.co/T8XsX9c27k https://t.co/KHE0ZoDtjL
-
-
Mashup Score: 0
Background: Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-CoV-2 infection (PASC) is unknown. The objective of this stu
Source: papers.ssrn.comCategories: Cardiologists, Latest HeadlinesTweet-
#LongCovid is real. There are many potential implications Persistent detection of viral components is potentially playing a role We show that #Paxlovid works not just for acute #COVID19 But also ⬇️ #LongCovid symptoms & healthcare utilization https://t.co/aWg4fZMNM8 https://t.co/8c6kZ2KAPP
-
-
Mashup Score: 0
Simulations suggest deaths from COVID-19 could be cut in half if 80% of eligible patients took the antiviral therapy.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
If #Paxlovid achieved 80% uptake among eligible people with #COVID19 as many as half of deaths in a future Omicron-like surge could be avoided, according to a new report. https://t.co/s0q2x4Q16W
-
-
Mashup Score: 17
An FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Source: ABC NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
The data continues to accumulate: #Paxlovid does NOT seem to increase risk of so-called “rebound” (And: it decreases risk of hospitalization/severe disease for those who are high risk) https://t.co/s93z8ARNtg
-
-
Mashup Score: 11Nirmatrelvir and the Risk of Post–COVID-19 Condition - 1 year(s) ago
This cohort study examines the association of treatment with nirmatrelvir in the acute phase of COVID-19 and risk of post–COVID-19 condition.
Source: jamanetwork.comCategories: General Medicine News, Latest HeadlinesTweet-
Study: #Paxlovid reduces risk of long-term health problems, death from COVID-19 @WUSTLmedschool @JAMAInternalMed https://t.co/1ey37K67Sp https://t.co/ANi9kCb376
-
-
Mashup Score: 17Nirmatrelvir and the Risk of Post–COVID-19 Condition - 1 year(s) ago
This cohort study examines the association of treatment with nirmatrelvir in the acute phase of COVID-19 and risk of post–COVID-19 condition.
Source: jamanetwork.comCategories: Expert Picks, Latest HeadlinesTweet-
In people with #Covid19 and at least 1 risk factor for progression to severe illness, treatment with #Paxlovid during the acute phase was associated with reduced risk of #LongCovid https://t.co/YjDHxHhbU7
-
-
Mashup Score: 1
AMA Vice President of Science, Medicine and Public Health Andrea Garcia, JD, MPH, covers the latest news physicians need to know, including: new updates from…
Source: YouTubeCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The latest news physicians need to know, including: updates from the FDA on #Paxlovid, data from a recent study on increasing maternal mortality rate, and the @CDCgov warning on the spread of a deadly fungus. https://t.co/818NHNOzVL https://t.co/SESt8wvWgL
-
Our Study @CIDJournal led by @jeremyfaust @PaulSaxMD #Paxlovid for Covid-19 in #Young (18-50) Vaccinated Patients with comorbidities (ie #CVD #Cancer #cardioonc) requiring frequent healthcare improves outcomes⬇️#death #hospitalization #Emergency visits https://t.co/tkdeV0XFNv